Results 241 to 250 of about 268,538 (298)

Preoperative use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diuretics increases the risk of dehydration after ileostomy formation: population-based cohort study. [PDF]

BJS Open
de la Motte L, Nordenvall C, Martling A, Buchli C.   +3 more
europepmc   +1 more source

Pre-operative maintenance of angiotensin-converting enzyme inhibitors is not associated with acute kidney injury in cardiac surgery patients with cardio-pulmonary bypass: a propensity-matched multicentric analysis. [PDF]

Front Pharmacol
Guilleminot P, Andrei S, Nguyen M, Abou-Arab O, Besnier E, Bouhemad B, Guinot PG, Collaborator study group.   +7 more
europepmc   +1 more source

Efficacy of traditional Chinese medicine versus angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and their combinations in the treatment of IgA nephropathy: a systematic review and network meta-analysis. [PDF]

Front Pharmacol
Ma S, Jiang Y, Qian L, Wang M, Xu S, Wang G.   +5 more
europepmc   +1 more source

Cardiorenal effects of dual blockade with Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people with CKD: analysis of routinely collected data with emulation of a reference trial (ONTARGET)

Baptiste PJ, Wong AY, Schultze A, Clase CM, Leyrat C, Williamson E, Powell E, Mann JF, Cunnington M, Teo K, Bangdiwala SI, Gao P, Wing K, Tomlinson L.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Angiotensin-Converting Enzyme Inhibitors

Medical Clinics of North America, 1988
There is convincing evidence that ACE inhibitors, alone or in combination with a diuretic, effectively lower blood pressure in patients with all grades of essential or renovascular hypertension and that they are of particular benefit as adjunctive therapy in patients with congestive heart failure.
Roger K. Ferguson, Peter H. Vlasses, Heschi H. Rotmensch   +2 more
  +8 more sources

Angiotensin-Converting Enzyme Inhibitors

Journal of Hypertension, 1991
The introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension and heart failure is probably the most important advance in cardiovascular pharmacotherapy in the last few decades. Although the role of the renin-angiotensin system (RAS) in cardiovascular diseases had been investigated extensively for more than 70 yr,
Irene Gavras, Haralambos Gavras
openaire   +5 more sources

Angiotensin-converting enzyme inhibitors

Critical Care Nurse, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
BL Herlihy, JT Herlihy
openaire   +5 more sources

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?

Journal of the American Medical Association (JAMA), 2020
Coronavirus disease 2019 (COVID-19) is a current pandemic infection caused by a positive-sense RNA virus named the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The particularly infectious capacity of the virus, along with mortality rates
A. Patel, A. Verma
semanticscholar   +1 more source